Trump Encourages Psychedelics for Mental Health as White House Fast-Tracks Research
President Donald Trump has launched a new initiative to accelerate psychedelic research for mental health treatment, marking a significant policy shift from his first administration. The move aims to advance studies involving substances such as MDMA, psilocybin, and ibogaine as potential therapies for conditions including post-traumatic stress disorder (PTSD), depression, and addiction.
According to a report by CNBC, the Trump administration has taken steps to speed up the development and regulatory review of psychedelic-assisted therapies, sparking both optimism and debate within the medical community.
What Happened?
In April 2026, President Trump signed an executive order directing federal agencies to accelerate research into psychedelic compounds for mental health treatment.
...
